Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Centaurus Biophrama Co., Ltd.

Yuliang Li

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Dengming Xiao

Yongxin Han

Yong Peng

Hong Luo

Yuandong Hu

Xijie Liu

Li Zhu

Xinhe Xu

Hui Zhang

Yinghui Sun

Fansheng Kong

Xiquan Zhang

Na Zhao

Yan Zhu

Huting Wang

Rong Yu

Zhe Wang

Wei Hu

Zhihua Liu

Ling Yang

Yu Shen

Rui Zhao

Zhi Liang

Honghao Yu

Shulong Wang

Xinlu Li

Feng Gong

Jijun Li

Zanping Wang

Quan Hu

Gen Li

Wei Wu

Sheng Zhao

Liang Cheng

He Wang

Qiong Wu

Xin Tian

Shanchun Wang

Aiming Zhang

Ying Sun

Liguang Dai

Xiaowei Duan

Yin Wang

Yuanyuan Huang

Ruiyu Zhao

Xiaofeng Zhai

Jian Sun

Yongheng Wei

Shixin Wang

Shousong Cao

Lipeng Zhang

Chonglong Li

Jia Tang

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase. 

Pyrrolopyrimidine compound

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers. 

Antitumor compound targeting IDH2 mutation and method of use thereof

The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition. 

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers. 

Inhibitor of bruton's tyrosine kinase

The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Pyridine-substituted 2-aminopyridine protein kinase inhibitors

The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolite, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and are further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provides the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. 

Inhibitors of bruton's tyrosine kinase

The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo. 

Quinazoline derivative and preparation method therefor

The present invention discloses substituted 2-aminopyridine derivatives as protein kinase inhibitors; specifically, the invention relates to 2-aminopyridine derivatives having protein kinase inhibitory properties, their manufacture, pharmaceutical compositions containing them, and use of the compounds and the pharmaceutical compositions thereof for the treatment of diseases associated with protein kinase.

Substituted 2-aminopyridine protein kinase inhibitor

The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition. 

Kinase modulating compounds, compositions containing the same and use thereof

The invention provides novel substituted 6-arylamino pyridone carboxamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, poly-morph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans. 

6-arylamino pyridone carboxamide as MEK inhibitors

The present disclosure relates to a compound of formula I, a pharmaceutical composition thereof and the use thereof as an anti-tumor drug. 

Compound of camptothecin and preparation and use thereof

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.

2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors

The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions. 

Arylalkene derivatives and use thereof as selective estrogen receptor modulators

Growing community of inventors

Beijing, China

Dengming Xiao